METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic r...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WANG, Maria, Yinglin TROTTER, Matthew William, Burnell COUTO, Suzana, Sturlini CHOPRA, Rajesh KLIPPEL, Anke HOLLENBACH, Paul BREIDER, Mike MACBETH, Kyle HAVENS, Courtney, G REN, Yan HAGNER, Patrick GANDHI, Anita |
| description | Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3077548A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3077548A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3077548A43</originalsourceid><addsrcrecordid>eNqNirEKwjAURbs4iPoP7wMsCK3oGpObJpCkJX0dOpUicRIt1N1fF6of4HQ559x19vZgU6uWdB1JgRG9DTZUpGJXEbS2Ush-qWxAHCHYIzDVmpTVumtBTsQKdMklnCPX-8bUXuzJd45t40C-h1uMCOoLVpEUQSK222x1G-9z2v12k5EGS5On6TmkeRqv6ZFeA5ricDody7Moiz8uH3Y4Owo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS</title><source>esp@cenet</source><creator>WANG, Maria, Yinglin ; TROTTER, Matthew William, Burnell ; COUTO, Suzana, Sturlini ; CHOPRA, Rajesh ; KLIPPEL, Anke ; HOLLENBACH, Paul ; BREIDER, Mike ; MACBETH, Kyle ; HAVENS, Courtney, G ; REN, Yan ; HAGNER, Patrick ; GANDHI, Anita</creator><creatorcontrib>WANG, Maria, Yinglin ; TROTTER, Matthew William, Burnell ; COUTO, Suzana, Sturlini ; CHOPRA, Rajesh ; KLIPPEL, Anke ; HOLLENBACH, Paul ; BREIDER, Mike ; MACBETH, Kyle ; HAVENS, Courtney, G ; REN, Yan ; HAGNER, Patrick ; GANDHI, Anita</creatorcontrib><description>Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170830&DB=EPODOC&CC=EP&NR=3077548A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170830&DB=EPODOC&CC=EP&NR=3077548A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WANG, Maria, Yinglin</creatorcontrib><creatorcontrib>TROTTER, Matthew William, Burnell</creatorcontrib><creatorcontrib>COUTO, Suzana, Sturlini</creatorcontrib><creatorcontrib>CHOPRA, Rajesh</creatorcontrib><creatorcontrib>KLIPPEL, Anke</creatorcontrib><creatorcontrib>HOLLENBACH, Paul</creatorcontrib><creatorcontrib>BREIDER, Mike</creatorcontrib><creatorcontrib>MACBETH, Kyle</creatorcontrib><creatorcontrib>HAVENS, Courtney, G</creatorcontrib><creatorcontrib>REN, Yan</creatorcontrib><creatorcontrib>HAGNER, Patrick</creatorcontrib><creatorcontrib>GANDHI, Anita</creatorcontrib><title>METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS</title><description>Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNirEKwjAURbs4iPoP7wMsCK3oGpObJpCkJX0dOpUicRIt1N1fF6of4HQ559x19vZgU6uWdB1JgRG9DTZUpGJXEbS2Ush-qWxAHCHYIzDVmpTVumtBTsQKdMklnCPX-8bUXuzJd45t40C-h1uMCOoLVpEUQSK222x1G-9z2v12k5EGS5On6TmkeRqv6ZFeA5ricDody7Moiz8uH3Y4Owo</recordid><startdate>20170830</startdate><enddate>20170830</enddate><creator>WANG, Maria, Yinglin</creator><creator>TROTTER, Matthew William, Burnell</creator><creator>COUTO, Suzana, Sturlini</creator><creator>CHOPRA, Rajesh</creator><creator>KLIPPEL, Anke</creator><creator>HOLLENBACH, Paul</creator><creator>BREIDER, Mike</creator><creator>MACBETH, Kyle</creator><creator>HAVENS, Courtney, G</creator><creator>REN, Yan</creator><creator>HAGNER, Patrick</creator><creator>GANDHI, Anita</creator><scope>EVB</scope></search><sort><creationdate>20170830</creationdate><title>METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS</title><author>WANG, Maria, Yinglin ; TROTTER, Matthew William, Burnell ; COUTO, Suzana, Sturlini ; CHOPRA, Rajesh ; KLIPPEL, Anke ; HOLLENBACH, Paul ; BREIDER, Mike ; MACBETH, Kyle ; HAVENS, Courtney, G ; REN, Yan ; HAGNER, Patrick ; GANDHI, Anita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3077548A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2017</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>WANG, Maria, Yinglin</creatorcontrib><creatorcontrib>TROTTER, Matthew William, Burnell</creatorcontrib><creatorcontrib>COUTO, Suzana, Sturlini</creatorcontrib><creatorcontrib>CHOPRA, Rajesh</creatorcontrib><creatorcontrib>KLIPPEL, Anke</creatorcontrib><creatorcontrib>HOLLENBACH, Paul</creatorcontrib><creatorcontrib>BREIDER, Mike</creatorcontrib><creatorcontrib>MACBETH, Kyle</creatorcontrib><creatorcontrib>HAVENS, Courtney, G</creatorcontrib><creatorcontrib>REN, Yan</creatorcontrib><creatorcontrib>HAGNER, Patrick</creatorcontrib><creatorcontrib>GANDHI, Anita</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WANG, Maria, Yinglin</au><au>TROTTER, Matthew William, Burnell</au><au>COUTO, Suzana, Sturlini</au><au>CHOPRA, Rajesh</au><au>KLIPPEL, Anke</au><au>HOLLENBACH, Paul</au><au>BREIDER, Mike</au><au>MACBETH, Kyle</au><au>HAVENS, Courtney, G</au><au>REN, Yan</au><au>HAGNER, Patrick</au><au>GANDHI, Anita</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS</title><date>2017-08-30</date><risdate>2017</risdate><abstract>Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3077548A4 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE |
| title | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T03%3A35%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WANG,%20Maria,%20Yinglin&rft.date=2017-08-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3077548A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |